Aurobindo Pharma gets U.S. FDA nod for Cephalexin tablets 

Published - October 01, 2024 07:31 pm IST - HYDERABAD

Generic drugmaker Aurobindo Pharma has received final approval from the U.S. Food and Drug Administration to manufacture and market Cephalexin Tablets USP, 250 mg and 500 mg.

Bioequivalent and therapeutically equivalent to the reference listed drug Keflet Tablets, 250 mg and 500 mg, of Eli Lilly and Company, the product is expected to be launched by December, Aurobindo Pharma said on Tuesday.

Aurobindo has been granted Competitive Generic Therapy (CGT) designation for Cephalexin Tablets USP, 250 mg and 500 mg, and eligible for 180 days of shared generic drug exclusivity. Cephalexin Tablets USP, 250 mg and 500 mg, are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms, it said in a release.

Aurobindo Pharma now has 523 ANDA approvals (506 final approvals and 17 tentative approvals) from the U.S. FDA. The company’s shares closed 1.53% lower at Rs.1,438.55 apiece on the BSE.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.